A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection

An overview of Guselkumab, an IL-23-targeted biologic therapy, including its mechanism of action, approved indications, and clinical evidence in psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Top Stories

Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology

Bone Marrow Protection Throughout Chemotherapy: Trilaciclib Approved for a New Indication, Extending from First-Line to Post-Relapse Treatment

Latest Coverage

The 30-Year Chemotherapy Standard Faces a New Challenge: China's PD-1 Serplulimab Breaks New Ground in Gastric Cancer Treatment
The 30-Year Chemotherapy Standard Faces a New Challenge: China’s PD-1 Serplulimab Breaks New Ground in Gastric Cancer...

Breaking Through for an Asian Cancer: China’s Innovation Rewrites the Future of Nasopharyngeal Cancer Treatment
What happens when a patient with nasopharyngeal cancer sees the disease progress again after first- and second-line t...

Sevabertinib for HER2-Mutant NSCLC in China: A New Targeted Treatment Option
From EGFR and ALK to ROS1, RET, MET, and HER2, advances in genetic testing and targeted therapies are enabling more p...

Current Status of Immunotherapy for Bladder Cancer: From BCG to Precision Combination Therapy
Bladder cancer is one of the most common malignancies of the urinary system. A substantial proportion of patients are...

Are Women More Prone to Thyroid Cancer? Causes and Prevention Explained
In recent years, the incidence of thyroid cancer has been rising globally. One notable feature is that women are affe...

From Health Checkups to Cancer Treatment: China’s Medical Travel Market Is Rapidly Expanding
From Health Checkups to Cancer Treatment: China’s Medical Travel Market Is Rapidly Expanding

In-Depth Analysis

A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection

Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology

Bone Marrow Protection Throughout Chemotherapy: Trilaciclib Approved for a New Indication, Extending from First-Line to Post-Relapse Treatment

The 30-Year Chemotherapy Standard Faces a New Challenge: China's PD-1 Serplulimab Breaks New Ground in Gastric Cancer Treatment